| Ambetter Health Arizona Clinical | Concert Genetic Testing: Hereditary Cancer Susceptibility | 2025-01-01 |
| Ambetter Health Michigan Meridian Clinical | Applied Behavioral Analysis Documentation Requirements | 2025-01-01 |
| BCBS Massachusetts | Overactive Bladder Medications | 2025-01-01 |
| Health Net Comm & Medi-Cal Plan | Genetic Testing for Hereditary Cancer Susceptibility | 2025-01-01 |
| HealthPartners | Filgrastim (Neupogen®, Nivestym®, Zarxio®, | 2025-01-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Occupational Therapy (OT) | 2025-01-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Iobenguane I-131 (Azedra) | 2025-01-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Intra-Arterial/Intravenous Therapeutic Procedures | 2025-01-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Tarlatamab-dlle (Imdelltra) | 2025-01-01 |
| BCBS Highmark Penn CPA/SEPA/WPA/NEPA | Nogapendekin alfa inbakicept-pmln (Anktiva) | 2025-01-01 |